These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
32. Risk of Recurrence for Clinical Stage I and II Patients With Teratoma Only at Primary Retroperitoneal Lymph Node Dissection. Liu NW; Cary C; Strine AC; Beck SD; Masterson TA; Bihrle R; Foster RS Urology; 2015 Nov; 86(5):981-4. PubMed ID: 26232690 [TBL] [Abstract][Full Text] [Related]
35. Laparoscopic retroperitoneal lymph node dissection: does it still have a role in the management of clinical stage I nonseminomatous testis cancer? A European perspective. Rassweiler JJ; Scheitlin W; Heidenreich A; Laguna MP; Janetschek G Eur Urol; 2008 Nov; 54(5):1004-15. PubMed ID: 18722704 [TBL] [Abstract][Full Text] [Related]
36. Laparoscopic retroperitoneal lymph-node dissection in the management of clinical stage I and II testicular cancer. Albqami N; Janetschek G J Endourol; 2005; 19(6):683-92; discussion 692. PubMed ID: 16053357 [TBL] [Abstract][Full Text] [Related]
39. Intraoperative, radio-guided sentinel lymph node mapping in laparoscopic lymph node dissection for Stage I testicular carcinoma. Satoh M; Ito A; Kaiho Y; Nakagawa H; Saito S; Endo M; Ohyama C; Arai Y Cancer; 2005 May; 103(10):2067-72. PubMed ID: 15803493 [TBL] [Abstract][Full Text] [Related]
40. Is modified retroperitoneal lymph node dissection (MRLND) still feasible in the treatment of patients with clinical stage I non-seminomatous testicular cancer? Sosnowski M; Jeromin L; Płuzańska A Int Urol Nephrol; 1994; 26(4):471-7. PubMed ID: 7528180 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]